Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026)

Vertex Pharmaceuticals has reported Total Liabilities for 18 years, with the latest figure at $7.2 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 4.58% year-over-year to $7.2 billion in Q2 2026; TTM through Jun 2026 was $7.2 billion, a 4.58% increase from a year earlier, with the FY2025 full-year figure at $7.0 billion, up 13.94% from the prior year.
• Total Liabilities was $7.2 billion for Q2 2026 at Vertex Pharmaceuticals, up from $7.1 billion in the prior quarter.
• The five-year high for Total Liabilities was $7.5 billion in Q3 2025, with the low at $3.3 billion in Q1 2022.
• Average Total Liabilities over 5 years is $5.6 billion, with a median of $5.4 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities soared 41.79% in 2023, then increased 4.58% in 2026.
• Over 5 years, Total Liabilities stood at $4.2 billion in 2022, then advanced by 21.51% to $5.1 billion in 2023, then climbed by 18.91% to $6.1 billion in 2024, then climbed by 13.94% to $7.0 billion in 2025, then grew by 2.84% to $7.2 billion in 2026.
• The last three Total Liabilities figures came in at $7.2 billion (Q2 2026), $7.1 billion (Q1 2026), and $7.0 billion (Q4 2025), per Business Quant data.